SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Syncom Formulations (India) Ltd

BSE: 524470 NSE: SYNCOMF ISIN: INE312C01025
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Syncom Formulations (India) Ltd belong to?
Syncom Formulations (India) Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Syncom Formulations (India) Ltd a good quality company?
Syncom Formulations (India) Ltd is a average quality company, based on a somewhat consistent 10 year financial track record.
Q.3 Is Syncom Formulations (India) Ltd undervalued or overvalued?
Syncom Formulations (India) Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Syncom Formulations (India) Ltd a good buy now?
Syncom Formulations (India) Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd revenue growth is 79.2% for FY-2025 , which is above its 5 year CAGR of 17.6% , indicating faster growth.
Q.2 Gross Profit margin of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd Gross profit margin which is the profit after deduction of direct costs, is 15.1% for FY-2025 , which is above its 5 year median of 14.1% , indicating increasing margins.
Q.3 Operating Profit Margin of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 11.56% for FY-2025 , which is above its 5 year median of 10.78% indicating increasing margins.
Q.4 Net Profit Margin of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd Net Profit Margin is 10.56% for FY-2025 , is above with its 5 year median of 9.14%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 15.1 14.1
Operating Profit Margin 11.56 10.78
Net Profit Margin 10.56 9.14
Q.5 Return on Asset of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd Return on Asset is 12.13%, which is above its 5 year historical median of 6.6%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd Return on equity is 15.61% for FY-2025 , which is above its historical median of 10.02%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd Return on capital employed is 18.66% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 14%, indicating value creation.
Q.8 Cash conversion cycle of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd Cash conversion cycle is 78 days, below its historical median of 111 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 1.15 0.73
ROE 15.61 10.02
ROCE 18.66 10.61
Cash Conversion Cycle 78 days 111 days
Q.9 Debt to Equity ratio of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd Debt-to-Equity ratio is 0.01 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd Debt to cash flow from operations is 0.17 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Syncom Formulations (India) Ltd?
Promoters hold 50.57% of the Syncom Formulations (India) Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Syncom Formulations (India) Ltd vs industry peers?
Syncom Formulations (India) Ltd revenue CAGR is 17.63% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 462.9 137.1
Gross Profit 69.9 15.1
Operating Profit 54 16
Net Profit 49 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 1.15 0.8
ROE 15.61 8.91
ROCE 18.66 11.59
Cash Conversion Cycle (days) 77.67 76

Valuation & price assessment

Q.1 Stock return of Syncom Formulations (India) Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 18.1% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 18.1% 28.5% 32.4% -18.4%
Q.3 Valuation ratios of Syncom Formulations (India) Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 19.02 9.92 40.28
Price to Book 3.32 0.95 2.77
Price to Sales 2.62 0.78 2.65
EV to EBITDA 13.55 6.20 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×